JAK2, CALR, MPL and ASXL1 mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms

Haematologica. 2018 Feb;103(2):e63-e68. doi: 10.3324/haematol.2017.178988. Epub 2017 Nov 16.

Authors

Waihay J Wong^{1

2}, Robert P Hasserjian^{2

3}, Geraldine S Pinkus^{1

2}, Lawrence J Breyfogle^{4

5}, Ann Mullally^{2

5}, Olga Pozdnyakova^{6

2}

Affiliations

¹ Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
² Harvard Medical School, Boston, MA, USA.
³ Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
⁴ Tufts University School of Medicine, Boston, MA, USA.
⁵ Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
⁶ Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA opozdnyakova@bwh.harvard.edu.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Bone Marrow Examination
Calreticulin / genetics
Humans
Janus Kinase 2 / genetics
Middle Aged
Mutation*
Myeloproliferative Disorders / genetics*
Philadelphia Chromosome
Receptors, Thrombopoietin / genetics
Repressor Proteins / genetics

Substances

ASXL1 protein, human
Calreticulin
Receptors, Thrombopoietin
Repressor Proteins
MPL protein, human
JAK2 protein, human
Janus Kinase 2

Grants and funding

R01 HL131835/HL/NHLBI NIH HHS/United States